ERBB2 and ovarian carcinoma: CP724714, a selective (ErbB2; Her-2/neu) tyrosine kinase inhibitor to inhibit ErbB2 receptor autophosphorylation in intact cells, has been used in breast cancer cell lines [26] and SKOV3 ovarian cancer cells [27], which had significant decline on both survival after treated with CP724714.